A Retrospective Study of the Application of Dupilumab After Endoscopic Expanded Sinus Surgery for Eosinophilic Sinusitis with Nasal Polyps

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109464

Enrollment

Unknown

Registered

2025-09-18

Start date

2025-04-30

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic sinusitis with nasal polyps

Interventions

The group undergoing expanded sinusotomy combined with the use of dupilumab:NA

Dupilumab is not used after the expanded sinusotomy group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for eosinophilic sinusitis with nasal polyps (pathological examination of polyp specimens showing Eos > 10/HPF); 2. Underwent endoscopic expanded sinus surgery; 3. Postoperative follow-up and medical treatment; 4. Postoperative treatment with dupilumab;

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete medical records.

Design outcomes

Primary

Measure	Time frame
olfactory Sniffen stick's score;Lund-Kennedy score;Visual Analog Scale (VAS) score;SNOT-22 score;	—

Countries

China

Contacts

Public ContactZhou Jianbo

Hunan Provincial People's Hospital

173700119@qq.com+86 731 8392 9258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026